Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on January 30, 2019. The filing primarily reports the entry into a material definitive agreement for an underwritten public offering of common stock. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The filing details a new equity offering and the closing of a prior offering. Specific financial metrics such as revenue, profit, or operating cash flow are not provided in this document.
- New Offering (Jan 30, 2019): 5,323,530 shares at $0.17 per share.
- Net Proceeds (New Offering): Approximately $841,650 (after underwriting discounts, before expenses).
- Underwriter Purchase Price: $0.1581 per share.
- Underwriter Warrants (New Offering): 346,030 shares (6.5% of offering), exercisable at $0.2125 per share for 5 years.
- Offering Expenses: Includes $15,000 non-accountable expenses, up to $40,000 for underwriter legal fees, $10,000 clearing expenses, and a 1% management fee on gross proceeds.
- Prior Offering (Closed Jan 31, 2019): 1,561,177 shares sold; 101,477 warrants issued to underwriter designees at $0.2125 exercise price.
Material Changes
The primary material change is the significant increase in authorized equity capital through the new underwriting agreement. The Company is raising capital to support its operations, as indicated by the execution of the offering. The filing notes the closing of a smaller offering on January 31, 2019, which was announced on January 28, 2019.
Outlook, Risks, and Contingencies
The new offering is expected to close on or about February 4, 2019, subject to customary closing conditions. The Underwriting Agreement includes customary representations, warranties, and indemnification provisions. The issuance of underwriter warrants is subject to the exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933. The filing does not contain specific forward-looking guidance on revenue or product milestones.
Key Facts for Investor Verification
- Verify the actual closing date and final net proceeds of the January 30, 2019 offering.
- Confirm the total dilution impact from the issuance of 5,323,530 new shares plus 346,030 warrant shares.
- Review the Company's cash position post-closing to assess runway given the small net proceeds relative to typical biotech operational costs.
- Check subsequent filings for the utilization of the $841,650 in net proceeds.
- Monitor the exercise status of the underwriter warrants issued in both the January 28 and January 30 offerings.